Piramal Pharma Limited

NSEI:PPLPHARMA Stock Report

Market Cap: ₹308.8b

Piramal Pharma Dividends and Buybacks

Dividend criteria checks 0/6

Piramal Pharma is a dividend paying company with a current yield of 0.047%.

Key information

0.05%

Dividend yield

-3.4%

Buyback Yield

Total Shareholder Yield-3.4%
Future Dividend Yield0.4%
Dividend Growth133.5%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per share₹0.110
Payout ratio79%

Recent dividend and buyback updates

Recent updates

Piramal Pharma Limited (NSE:PPLPHARMA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Jan 31
Piramal Pharma Limited (NSE:PPLPHARMA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results

Oct 26
₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results

Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt

Oct 25
Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt

Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden

Jul 14
Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden

Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Jun 17
Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings

May 21
We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings

It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)

Mar 26
It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)

Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Feb 28
Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161

Feb 02
Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161

Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Nov 09
Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Aug 11
Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: PPLPHARMA is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.

Growing Dividend: PPLPHARMA is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.


Dividend Yield vs Market

Piramal Pharma Dividend Yield vs Market
How does PPLPHARMA dividend yield compare to the market?
SegmentDividend Yield
Company (PPLPHARMA)0.05%
Market Bottom 25% (IN)0.3%
Market Top 25% (IN)1.2%
Industry Average (Pharmaceuticals)0.7%
Analyst forecast (PPLPHARMA) (up to 3 years)0.4%

Notable Dividend: PPLPHARMA's dividend (0.047%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.26%).

High Dividend: PPLPHARMA's dividend (0.047%) is low compared to the top 25% of dividend payers in the Indian market (1.22%).


Earnings Payout to Shareholders

Earnings Coverage: PPLPHARMA is not paying a notable dividend for the Indian market.


Cash Payout to Shareholders

Cash Flow Coverage: PPLPHARMA is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 05:48
End of Day Share Price 2025/01/31 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Piramal Pharma Limited is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kunal RanderiaAxis Capital Limited
null nullAxis Capital Limited
Prakash AgarwalAxis Capital Limited